Compare SGP & GSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SGP | GSBD |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 932.9M | 1.0B |
| IPO Year | N/A | 2013 |
| Metric | SGP | GSBD |
|---|---|---|
| Price | $24.39 | $9.40 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 5 | 2 |
| Target Price | ★ $45.00 | $9.00 |
| AVG Volume (30 Days) | 59.1K | ★ 1.3M |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 13.49% |
| EPS Growth | N/A | ★ 87.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.68 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.15 | $8.66 |
| 52 Week High | $30.56 | $12.03 |
| Indicator | SGP | GSBD |
|---|---|---|
| Relative Strength Index (RSI) | 47.66 | 43.46 |
| Support Level | $20.95 | $8.89 |
| Resistance Level | $26.55 | $9.53 |
| Average True Range (ATR) | 1.42 | 0.22 |
| MACD | 0.19 | -0.02 |
| Stochastic Oscillator | 52.86 | 14.07 |
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.